- Home
- CAC vs AUTL Comparison
CAC vs AUTL Comparison
Compare CAC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- AUTL
- Stock Information
- Founded
- CAC 1875
- AUTL 2014
- Country
- CAC United States
- AUTL United Kingdom
- Employees
- CAC N/A
- AUTL N/A
- Industry
- CAC Major Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAC Finance
- AUTL Health Care
- Exchange
- CAC Nasdaq
- AUTL Nasdaq
- Market Cap
- CAC 688.3M
- AUTL 625.4M
- IPO Year
- CAC 1997
- AUTL 2018
- Fundamental
- Price
- CAC $39.80
- AUTL $1.32
- Analyst Decision
- CAC Buy
- AUTL Strong Buy
- Analyst Count
- CAC 3
- AUTL 5
- Target Price
- CAC $48.00
- AUTL $9.12
- AVG Volume (30 Days)
- CAC 55.1K
- AUTL 4.2M
- Earning Date
- CAC 10-28-2025
- AUTL 11-11-2025
- Dividend Yield
- CAC 4.17%
- AUTL N/A
- EPS Growth
- CAC 4.80
- AUTL N/A
- EPS
- CAC 3.11
- AUTL N/A
- Revenue
- CAC $197,501,000.00
- AUTL $29,934,000.00
- Revenue This Year
- CAC $42.11
- AUTL $641.63
- Revenue Next Year
- CAC $5.51
- AUTL $109.21
- P/E Ratio
- CAC $12.93
- AUTL N/A
- Revenue Growth
- CAC 21.74
- AUTL 185.17
- 52 Week Low
- CAC $34.53
- AUTL $1.11
- 52 Week High
- CAC $50.07
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- CAC 47.42
- AUTL 26.05
- Support Level
- CAC $39.82
- AUTL $1.30
- Resistance Level
- CAC $40.75
- AUTL $1.46
- Average True Range (ATR)
- CAC 0.79
- AUTL 0.09
- MACD
- CAC -0.06
- AUTL 0.01
- Stochastic Oscillator
- CAC 12.06
- AUTL 7.25
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.